Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study

BackgroundIn October 2020, Germany became the first country, worldwide, to approve certain mobile health (mHealth) apps, referred to as DiGA (Digitale Gesundheitsanwendungen, in German, meaning digital health applications), for prescription with costs covered by standard stat...

Full description

Bibliographic Details
Main Authors: Florian Dahlhausen, Maximillian Zinner, Linn Bieske, Jan P Ehlers, Philip Boehme, Leonard Fehring
Format: Article
Language:English
Published: JMIR Publications 2021-11-01
Series:JMIR mHealth and uHealth
Online Access:https://mhealth.jmir.org/2021/11/e33012
_version_ 1797735573703622656
author Florian Dahlhausen
Maximillian Zinner
Linn Bieske
Jan P Ehlers
Philip Boehme
Leonard Fehring
author_facet Florian Dahlhausen
Maximillian Zinner
Linn Bieske
Jan P Ehlers
Philip Boehme
Leonard Fehring
author_sort Florian Dahlhausen
collection DOAJ
description BackgroundIn October 2020, Germany became the first country, worldwide, to approve certain mobile health (mHealth) apps, referred to as DiGA (Digitale Gesundheitsanwendungen, in German, meaning digital health applications), for prescription with costs covered by standard statutory health insurance. Yet, this option has only been used to a limited extent so far. ObjectiveThe aim of this study was to investigate physicians’ and psychotherapists’ current attitudes toward mHealth apps, barriers to adoption, and potential remedies. MethodsWe conducted a two-stage sequential mixed methods study. In phase one, semistructured interviews were conducted with physicians and psychotherapists for questionnaire design. In phase two, an online survey was conducted among general practitioners, physicians, and psychotherapists. ResultsA total of 1308 survey responses by mostly outpatient-care general practitioners, physicians, and psychotherapists from across Germany who could prescribe DiGA were recorded, making this the largest study on mHealth prescriptions to date. A total of 62.1% (807/1299) of respondents supported the opportunity to prescribe DiGA. Improved adherence (997/1294, 77.0%), health literacy (842/1294, 65.1%), and disease management (783/1294, 60.5%) were most frequently seen as benefits of DiGA. However, only 30.3% (393/1299) of respondents planned to prescribe DiGA, varying greatly by medical specialty. Professionals are still facing substantial barriers, such as insufficient information (1135/1295, 87.6%), reimbursement for DiGA-related medical services (716/1299, 55.1%), medical evidence (712/1298, 54.9%), legal uncertainties (680/1299, 52.3%), and technological uncertainties (658/1299, 50.7%). To support professionals who are unsure of prescribing DiGA, extended information campaigns (1104/1297, 85.1%) as well as recommendations from medical associations (1041/1297, 80.3%) and medical colleagues (1024/1297, 79.0%) were seen as the most impactful remedies. ConclusionsTo realize the benefits from DiGA through increased adoption, additional information sharing about DiGA from trusted bodies, reimbursement for DiGA-related medical services, and further medical evidence are recommended.
first_indexed 2024-03-12T13:01:01Z
format Article
id doaj.art-f67a1dfee06c4d99a3ef9a5e1ab282b4
institution Directory Open Access Journal
issn 2291-5222
language English
last_indexed 2024-03-12T13:01:01Z
publishDate 2021-11-01
publisher JMIR Publications
record_format Article
series JMIR mHealth and uHealth
spelling doaj.art-f67a1dfee06c4d99a3ef9a5e1ab282b42023-08-28T19:49:42ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222021-11-01911e3301210.2196/33012Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods StudyFlorian Dahlhausenhttps://orcid.org/0000-0003-3730-8992Maximillian Zinnerhttps://orcid.org/0000-0001-9416-6113Linn Bieskehttps://orcid.org/0000-0002-8777-3705Jan P Ehlershttps://orcid.org/0000-0001-6306-4173Philip Boehmehttps://orcid.org/0000-0001-8906-4753Leonard Fehringhttps://orcid.org/0000-0002-3322-3724 BackgroundIn October 2020, Germany became the first country, worldwide, to approve certain mobile health (mHealth) apps, referred to as DiGA (Digitale Gesundheitsanwendungen, in German, meaning digital health applications), for prescription with costs covered by standard statutory health insurance. Yet, this option has only been used to a limited extent so far. ObjectiveThe aim of this study was to investigate physicians’ and psychotherapists’ current attitudes toward mHealth apps, barriers to adoption, and potential remedies. MethodsWe conducted a two-stage sequential mixed methods study. In phase one, semistructured interviews were conducted with physicians and psychotherapists for questionnaire design. In phase two, an online survey was conducted among general practitioners, physicians, and psychotherapists. ResultsA total of 1308 survey responses by mostly outpatient-care general practitioners, physicians, and psychotherapists from across Germany who could prescribe DiGA were recorded, making this the largest study on mHealth prescriptions to date. A total of 62.1% (807/1299) of respondents supported the opportunity to prescribe DiGA. Improved adherence (997/1294, 77.0%), health literacy (842/1294, 65.1%), and disease management (783/1294, 60.5%) were most frequently seen as benefits of DiGA. However, only 30.3% (393/1299) of respondents planned to prescribe DiGA, varying greatly by medical specialty. Professionals are still facing substantial barriers, such as insufficient information (1135/1295, 87.6%), reimbursement for DiGA-related medical services (716/1299, 55.1%), medical evidence (712/1298, 54.9%), legal uncertainties (680/1299, 52.3%), and technological uncertainties (658/1299, 50.7%). To support professionals who are unsure of prescribing DiGA, extended information campaigns (1104/1297, 85.1%) as well as recommendations from medical associations (1041/1297, 80.3%) and medical colleagues (1024/1297, 79.0%) were seen as the most impactful remedies. ConclusionsTo realize the benefits from DiGA through increased adoption, additional information sharing about DiGA from trusted bodies, reimbursement for DiGA-related medical services, and further medical evidence are recommended.https://mhealth.jmir.org/2021/11/e33012
spellingShingle Florian Dahlhausen
Maximillian Zinner
Linn Bieske
Jan P Ehlers
Philip Boehme
Leonard Fehring
Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study
JMIR mHealth and uHealth
title Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study
title_full Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study
title_fullStr Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study
title_full_unstemmed Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study
title_short Physicians’ Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study
title_sort physicians attitudes toward prescribable mhealth apps and implications for adoption in germany mixed methods study
url https://mhealth.jmir.org/2021/11/e33012
work_keys_str_mv AT floriandahlhausen physiciansattitudestowardprescribablemhealthappsandimplicationsforadoptioningermanymixedmethodsstudy
AT maximillianzinner physiciansattitudestowardprescribablemhealthappsandimplicationsforadoptioningermanymixedmethodsstudy
AT linnbieske physiciansattitudestowardprescribablemhealthappsandimplicationsforadoptioningermanymixedmethodsstudy
AT janpehlers physiciansattitudestowardprescribablemhealthappsandimplicationsforadoptioningermanymixedmethodsstudy
AT philipboehme physiciansattitudestowardprescribablemhealthappsandimplicationsforadoptioningermanymixedmethodsstudy
AT leonardfehring physiciansattitudestowardprescribablemhealthappsandimplicationsforadoptioningermanymixedmethodsstudy